Diosmetin ameliorates psoriasis-associated inflammation and keratinocyte hyperproliferation by modulation of PGC-1α / YAP signaling pathway

  • Int Immunopharmacol. 2024 Jun 15:134:112248. doi: 10.1016/j.intimp.2024.112248.
Dailin Yang  1 ,  Mingwei Peng  1 ,  Fengping Fu  1 ,  Wenjuan Zhao  1 ,  Baoshun Zhang  2
Affiliations
  • 1. College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, PR China.
  • 2. College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, PR China. Electronic address: [email protected].
PMID: 38749332 DOI: 10.1016/j.intimp.2024.112248
Abstract

Psoriasis, characterized by aberrant epidermal keratinocyte proliferation and differentiation, is a chronic inflammatory immune-related skin disease. Diosmetin (Dios), derived from citrus fruits, exhibits anti-inflammatory and anti-proliferative properties. In this study, IL-17A-induced HaCaT cell model and Imiquimod (IMQ)-induced mouse model were utilized to investigate the effects of Dios against psoriasis. The morphology and biomarkers of psoriasis were regarded as the preliminary evaluation including PASI score, skin thickness, H&E staining, EdU staining and inflammatory factors. Transcriptomics analysis revealed PGC-1α as a key target for Dios in ameliorating psoriasis. Specifically, Dios, through PGC-1α, suppressed YAP-mediated proliferation and inflammatory responses in psoriatic keratinocytes. In conclusion, Dios shows promise in psoriasis treatment and holds potential for development as targeted medications for application in psoriasis.

Keywords
Diosmetin (Dios); Inflammation; Proliferation; Proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α); Psoriasis; Yes-associated protein (YAP).
Products